Neurological function at hospital discharge, measured by cerebral performance category (CPC) · Patients with non‐trauma related out‐of‐hospital cardiac arrest
Continuous chest compression alone showed no clear difference in neurological outcomes at hospital discharge Measured as 'good' or… compared with interrupted chest compression plus artificial ventilation (moderate certainty).
1 finding from 1 review
Return of spontaneous circulation · Patients with non‐trauma related out‐of‐hospital cardiac arrest
1 finding from 1 review
Adverse effects · Patients with non‐trauma related out‐of‐hospital cardiac arrest
1 finding from 1 review
Quality of life · Patients with non‐trauma related out‐of‐hospital cardiac arrest
1 finding from 1 review
Adverse events · participants with haemophilia
The review found no eligible studies for this question.
1 finding from 1 review
Exercise for haemophilia 2016 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Quality of life · participants with haemophilia
The review found no eligible studies for this question.
1 finding from 1 review
Exercise for haemophilia 2016 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Pain · participants with haemophilia
The review found no eligible studies for this question.
1 finding from 1 review
Exercise for haemophilia 2016 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Functional ability · participants with haemophilia
The review found no eligible studies for this question.
1 finding from 1 review
Exercise for haemophilia 2016 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Joint health: Modified Colorado Score · participants with haemophilia
1 finding from 1 review
Proportion of participants without tumour response (CR+PR) · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).
1 finding from 1 review
Proportion of participants without serum AFP normalisation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).
1 finding from 1 review
Parasitological failure at 1 month · People with S. mansoni infection
It is very uncertain whether artesunate (12 mg/kg) plus praziquantel (40 mg/kg) changes parasitological failure at 1 month compared with praziquantel (40 mg/kg) alone (very low certainty).
1 finding from 1 review
Mortality Number of deaths at maximum · participants with unresectable hepatocellular carcinoma
External beam radiotherapy (EBRT) plus transarterial… may leads to lower all‐cause mortality (at maximum 1‐year compared with TACE alone (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Elevated alanine aminotransferase Length of · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated alanine aminotransferase Length of compared with TACE alone (very low certainty).
1 finding from 1 review
Elevated total bilirubin Length of · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated total bilirubin Length of compared with TACE alone (very low certainty).
1 finding from 1 review
Adverse effects: at least one serious adverse event · People with advanced non‐small cell lung cancer
It is very uncertain whether TG4010 added to chemotherapy changes participants with at least one serious adverse event compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Adverse events: most commonly occurring events (occurring in at least 10% of participants) · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).
1 finding from 1 review